Welcure Drugs (WELCURE) | Stock Overview & Key Data
Welcure Drugs Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹25.00 on September 19, 2005
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Welcure Drugs
WELCURE
|
370.78M Small-cap | 0.00% | -10.34% | -3.70% | -45.83% | -38.10% | -75.00% | -25.00% | 17.39% | -77.50% | 50.00% | -30.77% |
|
Entero Healthcare
ENTERO
|
54.69B Mid-cap | 0.29% | -5.86% | 12.11% | 12.06% | -0.64% | -4.75% | -1.12% | -1.12% | -1.12% | -1.12% | -1.12% |
|
NOVELIX
NOVELIX
|
1.16B Small-cap | 23.32% | 61.28% | 62.04% | 40.58% | 41.58% | 181.69% | 242.11% | 242.11% | 242.11% | 242.11% | 242.11% |
|
Royal Sense
ROYAL
|
924.51M Small-cap | 0.93% | -22.86% | -30.37% | -49.77% | -40.28% | -59.36% | -8.50% | -8.50% | -8.50% | -8.50% | -8.50% |
|
Amwill Health Care
AMWILL
|
669.92M Small-cap | 17.21% | 42.72% | 37.61% | 22.87% | -4.99% | -39.04% | -57.48% | -57.48% | -57.48% | -57.48% | -57.48% |
|
Trimurthi
TRIMURTHI
|
500.39M Small-cap | 23.32% | 61.28% | 62.04% | 40.58% | 41.58% | 169.35% | 768.13% | 774.86% | 1,174.19% | 381.71% | 381.71% |
Ownership & Short Interest
Calculate Your Welcure Drugs Investment Returns
Long-Term Investment Performance Analysis
Welcure Drugs stock price in Jul 2016 was ₹0.16, A ₹1,000.00 lump sum investment in Welcure Drugs made 9 years ago would be worth approximately ₹1,625.00 today, representing a solid return of 62.50%. This translates to an annualized return (CAGR) of 5.02%.
9 Years 10 Months Investment Scenario (Jul 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is WELCURE's 52-week high and low?
- In the last 52 weeks, Welcure Drugs reached a high of ₹1.44 (on N/A) and a low of ₹0.23 (on April 2, 2026).
- What is the market cap and P/E ratio for WELCURE?
- Curious about Welcure Drugs's size and valuation? Its market capitalization stands at 370.78M. When it comes to valuation, the P/E ratio (trailing twelve months) is 1.30, and the forward P/E (looking ahead) is N/A.
- Does WELCURE pay dividends? If so, what's the yield?
- As for dividends, Welcure Drugs isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Welcure Drugs's main competitors or similar companies to consider before investing?
When looking at Welcure Drugs, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Entero Healthcare
ENTERO54.69B Healthcare Medical Distribution -4.75% -1.12% NOVELIX
NOVELIX1.16B Healthcare Medical Distribution 181.69% 242.11% Royal Sense
ROYAL924.51M Healthcare Medical Distribution -59.36% -8.50% Amwill Health Care
AMWILL669.92M Healthcare Medical Distribution -39.04% -57.48% Trimurthi
TRIMURTHI500.39M Healthcare Medical Distribution 169.35% 768.13% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Welcure Drugs & Pharmaceuticals Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Welcure Drugs's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 2.12%, the Debt to Equity ratio from the most recent quarter is 91.72, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for WELCURE?
- Looking at Welcure Drugs's growth, its revenue over the trailing twelve months (TTM) was INR4B. Compared to the same quarter last year (YoY), quarterly revenue grew by -100.00%, and quarterly earnings saw a YoY growth of 157.30%.
- How much of WELCURE stock is held by insiders and institutions?
- Wondering who owns Welcure Drugs stock? Company insiders (like executives and directors) hold about 85.74% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.00%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.